Regulation of Death Receptors by Synthetic Retinoids

  • Shi-Yong Sun
Part of the Cancer Drug Discovery and Development book series (CDD&D)


The term retinoids refers to an entire group of natural and synthetic retinol (vitamin A) metabolites and analogs. They exert profound effects on growth, differentiation, and apoptosis of many cell types (1). Thus, they play important roles in regulating, among other things, embryonic development, hematopoiesis, bone formation, glucose and lipid metabolism, and carcinogenesis (1). Currently, retinoids are used clinically in the treatment of skin disorders such as acne and psoriasis, and in the prevention or treatment of certain types of cancer, such as the treatment of acute promyelocytic leukemia (APL) and cutaneous T-cell lymphoma, reversal of premalignant lesions, and inhibition of the development of second primary tumors (2,3).


Death Receptor Acute Promyelocytic Leukemia Human Lung Cancer Cell Synthetic Retinoid Death Receptor Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of the retinoids. In: Sporn MB, Roberts AB, Goodman DS (eds), The Retinoids, 2nd ed. Raven Press, New York: 1994:443–520.Google Scholar
  2. 2.
    Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41:41–55.PubMedCrossRefGoogle Scholar
  3. 3.
    Thacher SM, Vasaudevan J, Chandrartna RA. Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des 2000;6:25–58.PubMedCrossRefGoogle Scholar
  4. 4.
    Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940–945.PubMedGoogle Scholar
  5. 5.
    Piedrafita FJ, Pfahl M. Nuclear retinoid receptors and mechanism of action. In: Nau H, Blaner WS (eds), Retinoids: The Biochemical and Molecular Basis of Vitamin A and Retinoid Action. Springer-Verlag, Berlin: 1999:153–184.Google Scholar
  6. 6.
    Blumberg B, Evans RM. Orphan nuclear receptors—new ligands and new possibilities. Genes Dev 1998;12:3149–3155.PubMedGoogle Scholar
  7. 7.
    Freedman LP. Increasing the complexity of coactivation in nuclear receptor signaling. Cell 1999;97:5–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Schulman IG, Crombie D, Bissonnette RP, et al. RXR-specific agonists and modulators: a new retinoid pharmacology. In: Nau H, Blaner WS (eds), Retinoids: The Biochemical and Molecular Basis of Vitamin A and Retinoid Action. Springer-Verlag, Berlin: 1999:215–235.Google Scholar
  9. 9.
    Shroot, Gibson DFC, Lu XP: Retinoid receptor-selective agonists and their action in skin. In: Nau H, Blaner WS (eds), Retinoids: The Biochemical and Molecular Basis of Vitamin A and Retinoid Action. Springer-Verlag, Berlin: 1999:539–559.Google Scholar
  10. 10.
    Geradts J., Chen JY, Russell EK, Yankaskas JR, Nieves L, Minna JD. Human lung cancer cells exhibit resistance to retinoic acid treatment. Cell Growth Differ 1993;4:799–809.PubMedGoogle Scholar
  11. 11.
    Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells. Mol Pharmacol 1999;55:403–410.PubMedGoogle Scholar
  12. 12.
    Sun SY, Yue P, Shroot B., et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 1997;57:4931–4939.PubMedGoogle Scholar
  13. 13.
    Ulukaya E, Wood EJ. Fenretinide and its relation to cancer. Cancer Treat Rev 1999;25:229–235.PubMedCrossRefGoogle Scholar
  14. 14.
    Sun SY, Yue P, Mao L, et al. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 2000;6:1563–1573.PubMedGoogle Scholar
  15. 15.
    Brogden RN, Goa KE. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs 1997;53:511–519.PubMedGoogle Scholar
  16. 16.
    DiSilvestro PA, DiSilvestro JM, Lernhardt W, Pfahl M, Mannel RS. Treatment of cervical intraepithelial neoplasia levels 2 and 3 with adapalene, a retinoid-related molecule. J Lower Genital Tract Dis 2001;5:33–37.CrossRefGoogle Scholar
  17. 17.
    Lu XP, Fanjul A, Picard N, et al. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat Med 1997;3:686–690.PubMedCrossRefGoogle Scholar
  18. 18.
    Schadendorf D, Kern MA, Artuc M, et al. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol 1996;135:1889–1898.PubMedCrossRefGoogle Scholar
  19. 19.
    Langdon SP, Rabiasz GJ, Ritchie AA, et al. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo. Cancer Chemother Pharmacol 1998;42:429–432.PubMedCrossRefGoogle Scholar
  20. 20.
    Sun S-Y, Yue P, Shroot B, Hong WK, Lotan R. Induction of apoptosis in human non-small cell lung carcinoma cells by a novel synthetic retinoid CD437. J Cell Physiol 1997;173:279–284.PubMedCrossRefGoogle Scholar
  21. 21.
    Sun SY, Yue P, Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000;19:4513–4522.PubMedCrossRefGoogle Scholar
  22. 22.
    Sun S-Y, Yue P, Chandraratna RAS, Tesfaigzi Y, Hong WK, Lotan R. Dual mechanisms of action of the retinoid CD437: nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent induction of apoptosis in UMSCC22B human head and neck squamous cell carcinoma cells. Mol Pharmacol 2000;58:508–514.PubMedGoogle Scholar
  23. 23.
    Adachi H, Preston G, Harvat B, Dawson MI, Jetten A. Inhibition of cell proliferation and induction of apoptosis by the retinoid AHPN in human lung carcinoma cells. Am J Respir Cell Mol 1998;18:823–333.Google Scholar
  24. 24.
    Li Y, Lin B, Agadir A, et al. Molecular determination of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol Cell Biol 1998;18:4719–4731.PubMedGoogle Scholar
  25. 25.
    Shao Z-M, Dawson MI, Li XS, et al. p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene; 1995;11:493–504.PubMedGoogle Scholar
  26. 26.
    Oridate N, Higuchi M, Suzuki S, Shroot B, Hong WK, Lotan R. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437). Int J Cancer 1997;70:484–487.PubMedCrossRefGoogle Scholar
  27. 27.
    Hsu, CA, Rishi AK, Li X-S, et al. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood 1997;89:4470–4479.PubMedGoogle Scholar
  28. 28.
    Gianni M, de The H. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. Leukemia 1999;13:739–749.PubMedCrossRefGoogle Scholar
  29. 29.
    Mologni L, Ponzanelli I, Bresciani F, et al. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood 1999;93:1045–1061.PubMedGoogle Scholar
  30. 30.
    Liang JY, Fontana JA, Rao JN, et al. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3. Prostate 1999;38:228–236.PubMedCrossRefGoogle Scholar
  31. 31.
    Zhang Y, Dawson MI, Mohammad R, et al. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood 2002;100:2917–2925.PubMedCrossRefGoogle Scholar
  32. 32.
    Sun SY, Yue P, Chen X, Hong WK, Lotan R. The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res 2002;62:2430–2436.PubMedGoogle Scholar
  33. 33.
    Hail N Jr, Lotan R. Synthetic retinoid CD437 promotes rapid apoptosis in malignant human epidermal keratinocytes and G1 arrest in their normal counterparts. J Cell Physiol 2001;186:24–34.PubMedCrossRefGoogle Scholar
  34. 34.
    Marchetti P, Zamzami N, Joseph B, et al. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 1999; 59:6257–6266.PubMedGoogle Scholar
  35. 35.
    Sun S-Y, Yue P, Wu GS, et al. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999;18:2357–2365.PubMedCrossRefGoogle Scholar
  36. 36.
    Sun S-Y, Yue P, Wu GS, et al. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 1999;59:2829–2833.PubMedGoogle Scholar
  37. 37.
    Sun S-Y, Yue P, Hong WK, Lotan R. Induction of Fas expression and augmentation of Fas/FasL-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 2000;60:6537–6543.PubMedGoogle Scholar
  38. 38.
    Sun S-Y, Yue P, Shroot B, Hong WK, Lotan R. Implication of c-Myc in apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999;18:3894–3901.PubMedCrossRefGoogle Scholar
  39. 39.
    Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–331.PubMedCrossRefGoogle Scholar
  40. 40.
    Gottlieb TM, Oren M. p53 and apoptosis. Semi Cancer Biol 1998;8:359–368.CrossRefGoogle Scholar
  41. 41.
    El-Deiry WS. Regulation of p53 downstream genes. Semi Cancer Biol 1998;8:345–357.CrossRefGoogle Scholar
  42. 42.
    Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 1995;15:3032–3040.PubMedGoogle Scholar
  43. 43.
    Sheard MA, Vojtesek B, Janakova L, Kovarik J, Zaloudik J. Up-regulation of Fas (CD95) in human p53 wild-type cancer cells treated with ionizing radiation. Int J Cancer 1997;73:757–762.PubMedCrossRefGoogle Scholar
  44. 44.
    Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997;99:403–413.PubMedCrossRefGoogle Scholar
  45. 45.
    Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R, Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998;282:290–293.PubMedCrossRefGoogle Scholar
  46. 46.
    Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998;188:2033–4205.PubMedCrossRefGoogle Scholar
  47. 47.
    Wu GS, Burns TF, McDonald ER 3rd, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141–143.PubMedCrossRefGoogle Scholar
  48. 48.
    Takimoto R, El-Deiry WS. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000;19(14):1735–1743.PubMedCrossRefGoogle Scholar
  49. 49.
    Guan B, Yue P, Clayman GL, Sun S-Y. Evidence that death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 2001;188:98–105.PubMedCrossRefGoogle Scholar
  50. 50.
    Cheng J, Liu C, Koopman WJ, Mountz JD. Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 1995;154:1239–1245.PubMedGoogle Scholar
  51. 51.
    Behrmann I, Walczak H, Krammer PH. Structure of the human APO-1 gene. Eur J Immunol 1994;24:3057–3062.PubMedCrossRefGoogle Scholar
  52. 52.
    Ossina NK, Cannas A, Powers VC, et al. Interferon-gamma modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J Biol Chem 1997;272:16,351–16,357.PubMedCrossRefGoogle Scholar
  53. 53.
    Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol 1999;19:2098–2108.PubMedGoogle Scholar
  54. 54.
    Dudley E, Hornung F, Zheng L, Scherer D, Ballard D, Lenardo M. NF-kappaB regulates Fas/APO-1/CD95-and TCR-mediated apoptosis of T lymphocytes. Eur J Immunol 1999;29:878–886.PubMedCrossRefGoogle Scholar
  55. 55.
    Kuhnel F, Zender L, Paul Y, et al. NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem, 2000;275:6421–6427.PubMedCrossRefGoogle Scholar
  56. 56.
    Lee SJ, Zhou T, Choi C, Wang Z, Benveniste EN. Differential regulation and function of Fas expression on glial cells. J Immunol 2000;164:1277–1285.PubMedGoogle Scholar
  57. 57.
    Li XR, Chong AS, Wu J, et al. Transcriptional regulation of Fas gene expression by GA-binding protein and AP-1 in T cell antigen receptor.CD3 complex-stimulated T cells. J Biol Chem, 1999;274:35,203–35,210.PubMedCrossRefGoogle Scholar
  58. 58.
    Lasham A, Lindridge E, Rudertl F, Onrust R, Watson J. Regulation of the human fas promoter by YB-1, Puralpha and AP-1 transcription factors. Gene 2000;252:1–13.PubMedCrossRefGoogle Scholar
  59. 59.
    Sheikh MS, Burns TF, Huang Y, et al. p53-dependent and-independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 1998;58:1593–1598.PubMedGoogle Scholar
  60. 60.
    Ravi R, Bedi GC, Engstrom LW, et al. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat Cell Biol 2001;3:409–416.PubMedCrossRefGoogle Scholar
  61. 61.
    Guan B, Yue P, Lotan R, Sun S-Y. Evidence that the death receptor 4 is regulated by activator protein 1. Oncogene 2002;21:3121–3129.PubMedCrossRefGoogle Scholar
  62. 62.
    Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815–818.PubMedCrossRefGoogle Scholar
  63. 63.
    Pan G, O’Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111–113.PubMedCrossRefGoogle Scholar
  64. 64.
    Piedrafita FJ, Pfahl M. Retinoid-induced apoptosis and Sp1 cleavage occur independently of transcription and require caspase activation. Mol Cell Biol 1997;17:6348–6358.PubMedGoogle Scholar
  65. 65.
    Ponzanelli I, Gianni M, Giavazzi R, et al. Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. Blood 2000;95:2672–2682.PubMedGoogle Scholar
  66. 66.
    Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770–776.PubMedCrossRefGoogle Scholar
  67. 67.
    Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MR, Yagita H. Nature’s TRAIL—on a path to cancer immunotherapy. Immunity. 2003;18:1–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255–260.PubMedCrossRefGoogle Scholar
  69. 69.
    Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420–430.PubMedCrossRefGoogle Scholar
  70. 70.
    Gibson SB, Oyer R, Spalding AC, Anderson SM, Johnson GL. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol 2000;20:205–212.PubMedCrossRefGoogle Scholar
  71. 71.
    Gliniak B, Le T. Tumor necrosis factor-related apoptosis-inducing ligand’s antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 1999;59:6153–6158.PubMedGoogle Scholar
  72. 72.
    Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 2000;60:847–853.PubMedGoogle Scholar
  73. 73.
    Mizutani Y, Nakao M, Ogawa O, Yoshida O, Bonavida B, Miki T. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 2001;165:263–270.PubMedCrossRefGoogle Scholar
  74. 74.
    Nimmanapalli, R, Perkins CL, Orlando M, O’Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001;61:759–763.PubMedGoogle Scholar
  75. 75.
    Nimmanapalli R, Porosnicu M, Nguyen D,’ et al. Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Clin Cancer Res 2001;7:350–357.PubMedGoogle Scholar
  76. 76.
    Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res 2001;61:1645–1651.PubMedGoogle Scholar
  77. 77.
    Lee YJ, Lee KH, Kim HR, et al. Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. Oncogene 2001;20:1476–1485.PubMedCrossRefGoogle Scholar
  78. 78.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001;81:380–390.PubMedCrossRefGoogle Scholar
  79. 79.
    Cuello M, Ettenberg SA, Clark AS, et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001;61:4892–4900.PubMedGoogle Scholar
  80. 80.
    Rohn TA, Wagenknecht B, Roth W, et al. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 2001;20:4128–4137.PubMedCrossRefGoogle Scholar
  81. 81.
    Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155–162.PubMedGoogle Scholar
  82. 82.
    Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res 2000;60:7149–7155.PubMedGoogle Scholar
  83. 83.
    Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001;7:680–686.PubMedCrossRefGoogle Scholar
  84. 84.
    Wang Q, Ji Y, Wang X, Evers BM. Isolation and molecular characterization of the 5′-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 2000;276:466–471.PubMedCrossRefGoogle Scholar
  85. 85.
    Gong B, Almasan A. Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 2000;278:747–752.PubMedCrossRefGoogle Scholar
  86. 86.
    Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 2002;277:36,602–36,610.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Authors and Affiliations

  • Shi-Yong Sun
    • 1
  1. 1.Winship Cancer InstituteEmory University School of MedicineAtlanta

Personalised recommendations